Q-omics provides the consensus-scored ADRA2B profile across patient tissues and cancer cell-line models. ADRA2B expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ADRA2B is differentially expressed in 12, with the highest sampling consensus in KIRP. Additionally, ADRA2B RNA expression shows 15,475 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, KIRP, and LSCC as cancer lineages where ADRA2B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ADRA2B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ADRA2B survival associations across molecular data types. ADRA2B RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ADRA2B RNA expression–survival associations across cancer types. High ADRA2B expression shows unfavorable associations in UVM, COAD and LGG, but favorable associations in LIHC, THCA and KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ADRA2B RNA expression.
This table summarizes ADRA2B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRP for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ADRA2B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ADRA2B shows lower tumor expression in KIRP, LIHC, BRCA and THCA and higher tumor expression in LUSC and KIRC. The KIRP box plot shows higher ADRA2B RNA expression in normal versus tumor tissue (log2 FC = −1.776, t-test p < 0.001).
This table shows molecular features associated with ADRA2B in patient tissues and cancer cell lines. In patient samples, ADRA2B shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ADRA2B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and UPPER_AERODIGESTIVE_TRACT.
